

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Genscript Biotech Corporation**

**金斯瑞生物科技股份有限公司\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1548)**

## **VOLUNTARY ANNOUNCEMENT**

# **RECEIVED FDA'S EMERGENCY USE AUTHORIZATION FOR THE WORLD'S FIRST SARS-COV-2 NEUTRALIZING ANTIBODY DETECTION KIT**

This is a voluntary announcement made by GenScript Biotech Corporation (the “**Company**” together with its subsidiaries, the “**Group**”).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that on 6 November 2020 (New York time), GenScript USA Inc. (“**GS USA**”), a direct wholly-owned subsidiary of the Company, was granted the Emergency Use Authorization (EUA) for the cPass<sup>™</sup> SARS-CoV-2 Neutralization Antibody Detection Kit (the “**cPass<sup>™</sup> Kit**”) by the U.S. Food and Drug Administration (“**FDA**”).

The cPass<sup>™</sup> Kit is the first commercially available test to specifically detect neutralizing antibodies in patient samples without the use of live virus. Neutralizing antibodies are widely recognized biomarkers of immunity. The test measures the presence of neutralizing antibodies in patients recovering from COVID-19 or receiving a vaccine.

The cPass<sup>™</sup> Kit utilizes pure proteins that can be produced in a more reproducible way compared with the conventional method for measuring neutralizing antibodies in patient samples. Unlike conventional method that requires BSL3 (Biosafety level-3) laboratory and live virus, the cPass Kit can be used in most standard laboratories with short turnaround time in approximately one hour, making it broadly available and much more consistent between different facilities.

“Unlike commercially available antibody-based tests that are routinely used for detecting prior exposure to the virus, the cPass<sup>™</sup> Kit can assess both prior exposure and the presence of neutralizing antibodies in convalescent patients,” said David Martz, Vice President of New Product Management in Life Science Group of the Group, “The cPass<sup>™</sup> Kit is also a valuable tool for assessing vaccine performance.”

“This cPass™ test can be used to screen animals for SARS-CoV-2 infection without modification, as it is a species independent,” added Professor Linfa Wang, director of Duke-National University of Singapore’s Emerging Infectious Diseases Program.

The cPass Kit has previously obtained the CE (Conformite Europeenne) mark in Europe. The Group is also in the process of applying for the Chinese Center of Medical Device Evaluation authorization for the cPass Kit in the People’s Republic of China. The Group and its business partners are making every effort possible to make this kit available globally.

## **INFORMATION ON THE GROUP AND GENSCRIPT USA INC.**

GenScript Biotech Corporation is a global biotechnology group. Based on its leading gene synthesis technology, the Group has developed four major platforms, including the (i) integrated global cell therapy platform, (ii) contract development and manufacturing organization (CDMO) platform, (iii) contract research organization (CRO) platform, and (iv) industrial synthetic products platform.

The Group was founded in New Jersey, United States in 2002 and listed on the Hong Kong Stock Exchange in 2015. The Group’s business operation spans over 100 countries and regions worldwide, with legal entities located in the United States, Mainland China, Hong Kong, Japan, Singapore, Netherlands and Ireland. The Group has provided premium, convenient, and reliable products and services to over 100,000 customers.

The Group has a number of intellectual property rights and technical secrets, including over 100 patents and over 270 patent applications. As of 30 June 2020, the Group’s products and services have been cited in over 51,000 international peer reviewed journal articles.

GS USA is a company incorporated under the laws of the State of Delaware of the United States and is a direct wholly-owned subsidiary of the Company.

**Shareholders and potential investors of the Company are advised to pay attention to investment risks and exercise caution when they deal or contemplate dealing in the securities of the Company.**

By Order of the Board  
**Genscript Biotech Corporation**  
**Wang Ye**  
*Executive Director*

Hong Kong, 8 November 2020

*As at the date of this announcement, the executive Directors are Ms. Wang Ye and Mr. Meng Jiange; the non-executive Directors are Dr. Zhang Fangliang, Dr. Wang Luquan, Mr. Pan Yuexin and Ms. Wang Jiafen; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian and Mr. Pan Jiuan.*

\* *For identification purposes only*